Why IMU is a multi multi bagger, page-31376

I would suggest the existing holders to read again the " letter to shareholder" and listen again to the reocrding of webinar 16/04. they don't want Imugene to fail but want it to be successful. they will need time.

In letter,
"We recognise that you are worried about your company’s performance, and future
prospects, and we can assure you that the Board and management are deeply focused on
getting it right"

For Azer-cell,
"We hope to update the market on azer-cel Phase 1b progress by the end of 1H or early in 2H
of 2025."

For OnCARlytics,
Our onCARlytics program is progressing through dose escalation, with higher dosing
expected to begin shortly — a higher dose potentially results in stronger clinical signals.

3.3 CF33
In the VAXINIA study, a bile tract cancer patient has remained in complete remission for
over two years where only ~8% typically respond, and for only a few months.
Two melanoma patients achieved partial responses, and 47% of all participants across
many dosing levels—despite being heavily pre-treated—achieved stable disease (the
cancer is neither growing nor shrinking significantly).

licensing deals, particularly HER-Vaxx
we have not yet signed a deal with any of our programs. Business development or licensing is a slow process and has to
remain confidential until a deal is signed. Lack of news does not mean we are doing nothing.

Let us be hoping Imugene is great science.

DYOR opinion only